Skip to main content
. 2020 Oct 6;10:16641. doi: 10.1038/s41598-020-73642-8

Table 4.

mRNA levels of studied genes in the population who received Bacillus Calmette–Guerin (BCG) therapy and association with response.

GENES Responsea n = 13 No responseb n = 15 p value**
PVRL4 122.90 [63.41–262.88]* 137.25 [33.37–638.75]* 0.53
MDM4 0.88 [0.50–1.24] 0.98 [0.71–1.63] 0.066
NFE2L2 1.87 [1.06–2.90] 1.59 [0.60–4.13] 0.77
PPARG 14.15 [5.91–18.73] 12.51 [2.26–17.67] 0.17
PIK3CA 1.81 [0.33–9.81] 0.62 [0.37–1.31] 0.39
PRKCI 4.07 [0.00–6.96] 3.71 [0.80–11.16] 0.7
FGFR3 27.94 [9.09–104.57] 73.47 [5.25–143.15] 0.037
TACC3 4.98 [1.36–9.32] 3.86 [1.39–12.08] 0.39
FBXW7 0.88 [0.60–1.26] 1.03 [0.64–1.74] 0.44
PAIP1 0.79 [0.63–1.96] 0.85 [0.10–1.09] 0.98
E2F3 2.13 [1.36–2.74] 2.17 [0.81–4.14] 0.73
SOX4 6.39 [3.53–11.76] 6.40 [1.91–12.88] 0.34
EGFR 1.34 [0.45–3.08] 0.92 [0.33–2.67] 0.35
ZNF703 1.09 [0.42–2.18] 1.27 [0.08–3.44] 0.39
PABPC1 2.21 [0.99–4.16] 2.02 [1.38–3.54] 0.27
YWHAZ 1.36 [1.14–3.69] 1.37 [0.68–2.48] 0.61
MYC 0.85 [0.60–1.82] 0.74 [0.30–2.36] 0.56
RXRA 2.04 [1.59–5.79] 1.96 [1.16–4.81] 0.98
GDI2 2.43 [1.50–3.19] 2.12 [0.92–3.10] 0.10
Ki67 8.21 [37.92–72.23] 29.36 [1.80–63.41] 0.27
CCND1 3.40 [0.43–17.88] 2.76 [1.27–10.71] 0.45
HRAS 1.29 [0.77–1.91] 1.30 [0.63–6.00] 0.60
ERBB3 20.49 [11.83–38.13] 19.20 [7.06–43.90] 0.98
MDM2 1.93 [1.17–3.67] 2.06 [0.94–6.08] 0.50
FRS2 0.65 [0.52–0.93] 0.71 [0.48–1.22] 0.24
ERBB2 7.91 [5.15–45.03] 6.43 [2.88–12.50] 0.20
CCNE1 3.78 [2.02–9.72] 3.78 [1.08–27.69] 0.85
ERCC2 1.48 [1.28–2.57] 1.78 [0.80–2.69] 0.45
BCL2L1 1.46 [0.76–1.72] 1.42 [0.75–2.35] 0.98

aNo recurrence or late recurrence (≥ 24 months).

bBCG-refractory or early recurrence (< 24 months).

*Median mRNA value [range].

**Kruskall Wallis H test.

Bold value is statistically significant (p < 0.05).